Zymeworks Inc Stock News

Gainers Intelligent Living Application Group Inc. (NASDAQ: ILAG) surged 77.7% to $9.35. Gravitas Education Holdings, Inc. (NASDAQ: GEHI) shares jumped 66% to $24.90. Avenue Therapeutics, Inc. (NASDAQ

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 200 points on Friday. The Dow traded down 0.74% to 29,817.07 while the NASDAQ fell 2.09% to 10,426.14. The

U.S. stocks traded lower, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session. Gravitas Education Holdings, Inc. (NASDAQ: GEHI) sh

U.S. stocks closed mixed with the Nasdaq Composite dropping more than 100 points on Tuesday. Here is the list of some big stocks recording losses in the previous session. AZZ Inc. (NYSE: AZZ) shares

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announ

Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p

Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. IVERIC bio, Inc. (NASDAQ: ISEE) rose 66.3% to close at $15.70

Zymeworks Inc. (NYSE:ZYME ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Jack Spinks - Associate Director of Investor Relations Ken Galbraith - Chair and CEO Dr. Neil

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announ

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

This includes Arcellx, Iovance Biotherapeutics, and ZymeWorks.

Over the past 3 months, 5 analysts have published their opinion on Zymeworks (NYSE:ZYME) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announ